Literature DB >> 25784989

TET1-mediated different transcriptional regulation in prostate cancer.

Jianhua Feng1, Qiang Wang2, Guangwei Li1, Xiangjian Zeng1, Shihang Kuang1, Xiaohua Li1, Youwei Yue1.   

Abstract

The recent studies demonstrated that the global 5-hydroxymethylcytosine (5 hmC) level decreased in prostate cancer (PCa) involved the 5-methylcytosine (5 mC) hydroxymethylase, Ten-eleven translocation (TET)1 reduction. 5 hmC and TET1 were both revealed a dual function in bivalent domain associated with developmental regulators in embryonic stem cell model. However, the mechanism underlying the DNA methylation and hydroxymethylation change mediated by TET1 downregulation in PCa remains unclear. Herein, using BSP to assess the 5 mC level in promoters of ten specific marker gene in PCa, our results present that Cdh1, Gstp1, Pten, Apc, Runx3 and Mgmt are observed to be hypermethylated in promoters and lower expression while Cyr61, Sema3c and Ptgs2 are reversed patterns compared to the normal prostate tissues. Furthermore, using ChIP methods to investigate the H3K4me3 and H3K27me3 patterns in promoters, these four markers are all demonstrated to be associated with Polycomb-repressed characterization and upregulated in response to TET1/PRC2 reduction in PCa. Thus, our findings reveal a distinct activating and repressive function of TET1-mediated transcriptional regulation in prostate cancer.

Entities:  

Keywords:  5 hmC; 5 mC; PRC2; Prostate cancer; TET1; methylation

Year:  2015        PMID: 25784989      PMCID: PMC4358444     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  34 in total

1.  A bivalent chromatin structure marks key developmental genes in embryonic stem cells.

Authors:  Bradley E Bernstein; Tarjei S Mikkelsen; Xiaohui Xie; Michael Kamal; Dana J Huebert; James Cuff; Ben Fry; Alex Meissner; Marius Wernig; Kathrin Plath; Rudolf Jaenisch; Alexandre Wagschal; Robert Feil; Stuart L Schreiber; Eric S Lander
Journal:  Cell       Date:  2006-04-21       Impact factor: 41.582

2.  Targeting epigenetics for the treatment of prostate cancer: recent progress and future directions.

Authors:  Jianqing Lin; Chenguang Wang; Wm Kevin Kelly
Journal:  Semin Oncol       Date:  2013-06       Impact factor: 4.929

3.  The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer.

Authors:  K Li; M K Chen; L Y Li; M H Lu; Ch K Shao; Z L Su; D He; J Pang; X Gao
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

4.  Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells.

Authors:  Hao Wu; Ana C D'Alessio; Shinsuke Ito; Zhibin Wang; Kairong Cui; Keji Zhao; Yi Eve Sun; Yi Zhang
Journal:  Genes Dev       Date:  2011-04-01       Impact factor: 11.361

5.  TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer.

Authors:  Hua-Lin Fu; Yue Ma; Lun-Gen Lu; Peng Hou; Bao-Jie Li; Wei-Lin Jin; Da-Xiang Cui
Journal:  J Biomed Nanotechnol       Date:  2014-07       Impact factor: 4.099

6.  Prostate cancer, version 2.2014.

Authors:  James L Mohler; Philip W Kantoff; Andrew J Armstrong; Robert R Bahnson; Michael Cohen; Anthony Victor D'Amico; James A Eastham; Charles A Enke; Thomas A Farrington; Celestia S Higano; Eric Mark Horwitz; Christopher J Kane; Mark H Kawachi; Michael Kuettel; Timothy M Kuzel; Richard J Lee; Arnold W Malcolm; David Miller; Elizabeth R Plimack; Julio M Pow-Sang; David Raben; Sylvia Richey; Mack Roach; Eric Rohren; Stan Rosenfeld; Edward Schaeffer; Eric J Small; Guru Sonpavde; Sandy Srinivas; Cy Stein; Seth A Strope; Jonathan Tward; Dorothy A Shead; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2014-05       Impact factor: 11.908

7.  Cyr61 is up-regulated in prostate cancer and associated with the p53 gene status.

Authors:  Hezhe Lv; Ellen Fan; Suozhu Sun; Xiaoxiao Ma; Xiaoyan Zhang; David M K Han; Yu-Sheng Cong
Journal:  J Cell Biochem       Date:  2009-03-01       Impact factor: 4.429

8.  Methylated genes as new cancer biomarkers.

Authors:  M J Duffy; R Napieralski; J W M Martens; P N Span; F Spyratos; F C G J Sweep; N Brunner; J A Foekens; M Schmitt
Journal:  Eur J Cancer       Date:  2009-01-12       Impact factor: 9.162

9.  Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.

Authors:  J-F Jhang; Y-H Jiang; H-C Kuo
Journal:  Int J Clin Pract       Date:  2013-12       Impact factor: 2.503

Review 10.  TET family proteins and their role in stem cell differentiation and transformation.

Authors:  Luisa Cimmino; Omar Abdel-Wahab; Ross L Levine; Iannis Aifantis
Journal:  Cell Stem Cell       Date:  2011-09-02       Impact factor: 24.633

View more
  13 in total

1.  APC methylation predicts biochemical recurrence of patients with prostate cancer: a meta-analysis.

Authors:  Yi Wang; Caibin Fan; Jiang Yu; Xizhi Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.

Authors:  Hao Li; Wang Jiang; Xue-Ni Liu; Li-Yun Yuan; Tian-Jiao Li; Shuo Li; Shuai-Shuai Xu; Wu-Hu Zhang; He-Li Gao; Xuan Han; Wen-Quan Wang; Chun-Tao Wu; Xian-Jun Yu; Hua-Xiang Xu; Liang Liu
Journal:  Oncogene       Date:  2020-08-04       Impact factor: 9.867

3.  Reduced hydroxymethylation characterizes medulloblastoma while TET and IDH genes are differentially expressed within molecular subgroups.

Authors:  Karina Bezerra Salomão; Gustavo Alencastro Veiga Cruzeiro; Ricardo Bonfim-Silva; Lenisa Geron; Fernando Ramalho; Fabiano Pinto Saggioro; Luciano Neder Serafini; Daniel Antunes Moreno; Rosane Gomes de Paula Queiroz; Simone Dos Santos Aguiar; Izilda Cardinalli; José Andres Yunes; Silvia Regina Brandalise; Maria Sol Brassesco; Carlos Alberto Scrideli; Luiz Gonzaga Tone
Journal:  J Neurooncol       Date:  2018-03-26       Impact factor: 4.130

4.  DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer.

Authors:  Kirill Litovkin; Aleyde Van Eynde; Steven Joniau; Evelyne Lerut; Annouschka Laenen; Thomas Gevaert; Olivier Gevaert; Martin Spahn; Burkhard Kneitz; Pierre Gramme; Thibault Helleputte; Sofie Isebaert; Karin Haustermans; Mathieu Bollen
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

5.  Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1.

Authors:  Lien Spans; Thomas Van den Broeck; Elien Smeets; Stefan Prekovic; Bernard Thienpont; Diether Lambrechts; R Jeffrey Karnes; Nicholas Erho; Mohammed Alshalalfa; Elai Davicioni; Christine Helsen; Thomas Gevaert; Lorenzo Tosco; Karin Haustermans; Evelyne Lerut; Steven Joniau; Frank Claessens
Journal:  Oncotarget       Date:  2016-04-26

6.  TET1 knockdown inhibits the odontogenic differentiation potential of human dental pulp cells.

Authors:  Li-Jia Rao; Bai-Cheng Yi; Qi-Meng Li; Qiong Xu
Journal:  Int J Oral Sci       Date:  2016-06-30       Impact factor: 6.344

7.  TET1-mediated DNA hydroxymethylation activates inhibitors of the Wnt/β-catenin signaling pathway to suppress EMT in pancreatic tumor cells.

Authors:  Jian Wu; Hongzhe Li; Minmin Shi; Youwei Zhu; Yang Ma; Yiming Zhong; Cheng Xiong; Hao Chen; Chenghong Peng
Journal:  J Exp Clin Cancer Res       Date:  2019-08-09

Review 8.  DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment.

Authors:  Hongming Zhu; He Zhu; Miao Tian; Dongying Wang; Jiaxing He; Tianmin Xu
Journal:  Front Genet       Date:  2020-04-09       Impact factor: 4.599

9.  Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.

Authors:  Alin Grelus; Dragos V Nica; Imola Miklos; Valerica Belengeanu; Ioan Ioiart; Cristina Popescu
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

Review 10.  Semaphorin 3C and Its Receptors in Cancer and Cancer Stem-Like Cells.

Authors:  Jing Hao; Jennifer S Yu
Journal:  Biomedicines       Date:  2018-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.